Memorial Hospital Research Laboratories
The Michael Roehrl Lab
An overarching theme of my laboratory’s work is the experimental investigation of the network behavior of biological systems relevant to human disease using a variety of biochemical, biophysical, molecular biological, and systems modeling approaches. A primary focus is the biology of gastrointestinal solid tumors such as colorectal and pancreatic cancers.
Wang JY, Roehrl MW, Roehrl VB, Roehrl MH. A master autoantigen-ome links alternative splicing, female predilection, and COVID-19 to autoimmune diseases. J Transl Autoimmun. 2022;5:100147. doi: 10.1016/j.jtauto.2022.100147. Epub 2022 Feb 25.
Ogawa M, Tanaka A, Namba K, Shia J, Wang JY, Roehrl MHA. Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer. Sci Rep. 2022 Feb 17;12(1):2767. doi: 10.1038/s41598-022-06772-w.
Omenn GS, Lane L, Overall CM, Paik YK, Cristea IM, Corrales FJ, Lindskog C, Weintraub S, Roehrl MHA, Liu S, Bandeira N, Srivastava S, Chen YJ, Aebersold R, Moritz RL, Deutsch EW. Progress Identifying and Analyzing the Human Proteome: 2021 Metrics from the HUPO Human Proteome Project. J Proteome Res. 2021 Dec 3;20(12):5227-5240. doi: 10.1021/acs.jproteome.1c00590. Epub 2021 Oct 20.
Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, Krug K, Clark DJ, Schnaubelt M, Chen L, da Veiga Leprevost F, Eguez RV, Yang W, Pan J, Wen B, Dou Y, Jiang W, Liao Y, Shi Z, Terekhanova NV, Cao S, Lu RJ, Li Y, Liu R, Zhu H, Ronning P, Wu Y, Wyczalkowski MA, Easwaran H, Danilova L, Mer AS, Yoo S, Wang JM, Liu W, Haibe-Kains B, Thiagarajan M, Jewell SD, Hostetter G, Newton CJ, Li QK, Roehrl MH, Fenyö D, Wang P, Nesvizhskii AI, Mani DR, Omenn GS, Boja ES, Mesri M, Robles AI, Rodriguez H, Bathe OF, Chan DW, Hruban RH, Ding L, Zhang B, Zhang H. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Clinical Proteomic Tumor Analysis Consortium. Cell. 2021 Sep 16;184(19):5031-5052.e26. doi: 10.1016/j.cell.2021.08.023.
Michael H. A. Roehrl, MD, PhD
Director, Precision Pathology Biobanking Center; Associate Pathologist
- Physician-scientist Michael Roehrl studies gastrointestinal cancers and other solid tumors using proteomic, proteogenomic, and immunoproteomic approaches. We focus on risk-stratifying biomarkers and autoantigens in cancer and autoimmunity.
- View physician profile
- Physician profile
To learn more about available postdoctoral opportunities, please visit our Career Center
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael H. A. Roehrl discloses the following relationships and financial interests:
Trans-Hit Biomarkers Inc.
Provision of Services
Universal Diagnostics (UDX)
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.